SEC Info - LadRx Corp.

SEC Info℠

Home

My Interests

Help

Please Sign In

LadRx Corp.
CA
SEC # 799698

Click to view...

Registrant

About

Filings

Files

Relationships

Names

Topics

Web

*As Of*	*Filing*	*Page*	*Title*	*Docs.*

4/14/23	S-1	1	About This Prospectus	1
7/28/23	DEF 14A	1	Advisory Vote to Approve the Compensation Paid to Our Named Executive Officers	2
		1	Advisory Vote to Approve the Frequency of Future Stockholder Advisory Votes to Approve the Compensation Paid to Our Named Executive Officers	2
		1	Amendments to Our Governing Documents to Declassify the Structure of Our Board of Directors	2
3/27/24	10-K	1	Business	2
4/14/23	S-1	1	Capitalization	1
3/27/24	10-K	1	Certain Relationships and Related Transactions, and Director Independence	1
		1	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	1
		1	Company's postulated mechanism of action for LADR-based drugs is as follows, The	2
7/28/23	DEF 14A	1	Compensation of Directors	2
11/14/23	10-Q	1	Condensed Consolidated Financial Statements (unaudited)	3
3/27/24	10-K	1	Consolidated Balance Sheets	2
		1	Consolidated Statements of Cash Flows	2
		1	Consolidated Statements of Operations	2
		1	Consolidated Statements of Stockholders' Equity (Deficit)	2
		1	Controls and Procedures	4
7/28/23	DEF 14A	1	Corporate Governance	2
3/27/24	10-K	1	COVID-19 endemic and its ongoing effects could adversely impact our business and prospects, including active and planned clinical trials by ImmunityBio and Zevra, The	1
		1	Cybersecurity	1
11/14/23	10-Q	1	Defaults Upon Senior Securities	2
4/14/23	S-1	1	Description of Securities to Be Registered	1
		1	Dilution	1
3/27/24	10-K	1	Directors, Executive Officers and Corporate Governance	1
		1	Disclosure Regarding Foreign Jurisdictions That Prevent Inspections	1
4/14/23	S-1	1	Dividend Policy	1
7/28/23	DEF 14A	1	Election of Directors	2
4/14/23	S-1	1	Executive and Director Compensation	1
3/27/24	10-K	1	Executive Compensation	3
		1	Exhibit and Financial Statement Schedules	1
11/14/23	10-Q	1	Exhibits	3
4/14/23	S-1	1	Experts	1
11/14/23	10-Q	1	Financial Information	3
3/27/24	10-K	1	Financial Statements and Supplementary Data	1
		1	Form 10-K Summary	1
7/28/23	DEF 14A	1	General Information	2
3/27/24	10-K	1	Impact and results of our exploration of any strategic alternatives are uncertain and may not be successful, The	1
11/14/23	10-Q	1	Index to Exhibits	3
4/14/23	S-1	1	Index to Financial Statements	1
		1	Legal Matters	1
3/27/24	10-K	1	Legal Proceedings	4
		1	Management's Discussion and Analysis of Financial Condition and Results of Operations	5
		1	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	1
4/14/23	S-1	1	Material U.S. Federal Income Tax Considerations	1
3/27/24	10-K	1	Mine Safety Disclosures	3
		1	Note on Forward-Looking Statements	1
		1	Notes to Consolidated Financial Statements	2
		1	Other Information	4
7/28/23	DEF 14A	1	Other Matters	2
3/27/24	10-K	1	Part I	1
11/14/23	10-Q	1	Part I. -- Financial Information	3
3/27/24	10-K	1	Part Ii	1
11/14/23	10-Q	1	Part Ii. -- Other Information	3
3/27/24	10-K	1	Part Iii	1
		1	Part Iv	1
7/28/23	DEF 14A	1	Pay Versus Performance	2
4/14/23	S-1	1	Power of Attorney	1
3/27/24	10-K	1	Principal Accountant Fees and Services	1
		1	Properties	1
7/28/23	DEF 14A	1	Proposal 1 -- Election of Directors	2
		1	Proposal 2 -- Amendments to Our Governing Documents to Declassify the Structure of Our Board of Directors	2
		1	Proposal 3 -- Ratification of the Appointment Weinberg & Company as Our Independent Registered Public Accounting Firm for the 2023 Fiscal Year	2
		1	Proposal 4 -- Advisory Vote to Approve the Compensation Paid to Our Named Executive Officers	2
		1	Proposal 5 -- Advisory Vote to Approve the Frequency of Future Stockholder Advisory Votes to Approve the Compensation Paid to Our Named Executive Officers	2
4/14/23	S-1	1	Prospectus Summary	1
7/28/23	DEF 14A	1	Proxy Statement	2
3/27/24	10-K	1	Quantitative and Qualitative Disclosures About Market Risk	4
7/28/23	DEF 14A	1	Ratification of the Appointment Weinberg & Company as Our Independent Registered Public Accounting Firm for the 2023 Fiscal Year	2
4/14/23	S-1	1	Related Party Transactions	1
3/27/24	10-K	1	Reports of Independent Registered Public Accounting Firm	2
		1	Reserved	1
4/14/23	S-1	1	Risk Factor Summary	1
3/27/24	10-K	1	Risk Factors	5
7/28/23	DEF 14A	1	Security Ownership of Certain Beneficial Owners and Management	3
3/27/24	10-K	1	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	1
		1	Signatures	4
4/14/23	S-1	1	Special Note Regarding Forward-Looking Statements	1
7/28/23	DEF 14A	1	Stockholder Proposals for the 2024 Annual Meeting of Stockholders	2
3/27/24	10-K	1	The Company's postulated mechanism of action for LADR-based drugs is as follows	2
		1	The COVID-19 endemic and its ongoing effects could adversely impact our business and prospects, including active and planned clinical trials by ImmunityBio and Zevra	1
		1	The impact and results of our exploration of any strategic alternatives are uncertain and may not be successful	1
4/14/23	S-1	1	Underwriting	1
11/14/23	10-Q	1	Unregistered Sales of Equity Securities and Use of Proceeds	3
3/27/24	10-K	1	Unresolved Staff Comments	1
4/14/23	S-1	1	Use of Proceeds	1
7/28/23	DEF 14A	1	Where You Can Find More Information	3

↑Top

LadRx Corp. CA SEC # 799698

157 Topics within the Past Year Past Two Years Past Three Years Past Four Years Past Five Years Entire Database

LadRx Corp.
CA
SEC # 799698

157 Topics
within the